A new twice-yearly HIV prevention injection, expected to be rolled out at about $40 (less than ₦70,000) per patient annually in Nigeria, has sparked both optimism and scepticism among health workers, patients, and advocates.
The drug, called lenacapavir, offers six months of protection with a s
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
kenneth Athekame
Athekame Kenneth is a politics, economy, and finance reporter whose work is anchored in sharp investigative storytelling. He brings analytical depth to every piece, drawing on a strong academic foundation that includes a degree in Economics, an MBA in International Trade, and a minor in Petroleum Economics from Lagos State University, Ojo. His reporting blends rigorous research with a keen eye for hidden truths, delivering stories that illuminate power, policy, and the forces shaping everyday lives.
